Full Press Release Details
DarioHealth Corp. (NASDAQ:DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it has entered into a strategic agreement with CCS Medical and their LivingConnected clinical program.
Through this strategic agreement and proprietary API, DarioHealth is partnering with CCS Medical by providing live data access to CCS Medical for patients that join the LivingConnected clinical program using the DarioHealth native smartphone app. In addition, CCS Medical will take an active role in the DarioHealth Insurance Provider Network, thereby further growing DarioHealth's expansion into the insurance reimbursement option launched earlier this year.
The LivingConnected program is a cellular-enabled diabetes management program designed to give diabetes patients access to live monitoring and guidance when they have an adverse reading or trend in their blood sugar levels.
The goal of LivingConnected is to help patients manage their diabetes in real time, which helps prevent complications and improve their quality of life. Results of live readings can be shared with others, allowing immediate health coaching from Registered Nurses and Certified Diabetes Educators. Ongoing reports and education are also part of the coordination of the patient's care.
Sean Browne, Chief Revenue Officer of CCS Medical, commented, "We are enthusiastic about the DarioHealth partnership and expect significant growth in this segment of our business, due to the innovative nature of the DarioHealth technology."
Erez Raphael, Chairman and CEO of DarioHealth, commented, "CCS Medical is a leading provider of home medical supplies for patients with chronic conditions, including diabetes. This is a natural fit for us as it further strengthens our position in the U.S. market, because through our API, CCS Medical can offer additional value-added services to their customers. With this partnership, we aim to continue our market expansion, which is critical for DarioHealth as it aims to ramp up sales and market share in the second half of the year."
Following the development of DarioHealth's proprietary API, DarioHealth expects to enter into further strategic alliances over the coming months.
About CCS Medical's LivingConnected ProgramCCS Medical, a leader with over 20 years of industry experience, is a leading provider of quality medical supplies for patients with chronic conditions. CCS Medical's LivingConnected program is an innovative mobile health solution, which enables those with diabetes to live healthier lives. This program brings needed visibility to the diabetic population and the exorbitant costs associated with this chronic disease. Through key elements of healthy living, the LivingConnected solution effectively manages the rising costs of diabetes. For more information on CCS Medical, visithttps://ccsmed.com.
About DarioHealth Corp.DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario(TM) Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visithttp://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking StatementsThis news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes its growth plans and prospects, its plans for the second half of 2017, and its expectations for further strategic alliances, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario(TM)) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.